Targeting a lipid receptor to improve stroke treatment
Lipid Receptor GPR31 as a Target for Anti-Thrombotic and Stroke Therapy
This study is looking at a special receptor called GPR31 to see if blocking it can help prevent blood clots and protect the brain during a stroke, which could lead to better treatments for stroke patients.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Oasis Pharmaceuticals NIH-funded |
| Lab location | 1 site (Lexington, United States) |
| Project ID | NIH-11137505 on NIH RePORTER |
What this research studies
This research investigates the lipid receptor GPR31 as a potential target for developing new therapies to prevent blood clots and protect the brain after a stroke. The approach focuses on understanding how bioactive fatty acids influence inflammation and metabolism, particularly in the context of stroke. By blocking GPR31, the researchers aim to create a safer and more effective treatment that not only prevents clot formation but also protects brain cells from damage during a stroke. This could lead to improved outcomes for stroke patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults aged 21 and older who are at risk of or have experienced an acute stroke.
Not a fit: Patients who are under 21 years old or those with conditions unrelated to stroke may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that reduce the risk of stroke-related disabilities and improve recovery outcomes for patients.
How similar studies have performed: Other research has shown promise in targeting lipid receptors for therapeutic purposes, indicating potential success for this novel approach.
Where this research is happening
Lexington, United States
- Oasis Pharmaceuticals — Lexington, United States (Active)
Researchers
- Principal investigator: Kuliopulos, Athan — Oasis Pharmaceuticals
- Study coordinator: Kuliopulos, Athan
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.